Literature DB >> 22847211

The relation of sTRAIL levels and quality of life in severe persistent allergic asthma patients using omalizumab.

Arzu Didem Yalcin, Atil Bisgin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22847211     DOI： 10.12659/msm.883249

Source DB:  PubMed          Journal:  Med Sci Monit        ISSN： 1234-1010


× No keyword cloud information.
  5 in total

1.  Soluble trail as a marker of efficacy of allergen-specific immunotherapy in patients with allergic rhinoconjunctivitis.

Authors:  Arzu Didem Yalcin; Saadet Gumuslu; Gizem Esra Parlak; Atil Bısgın
Journal:  Med Sci Monit       Date:  2012-10

Review 2.  An overview of the effects of anti-IgE therapies.

Authors:  Arzu Didem Yalcin
Journal:  Med Sci Monit       Date:  2014-09-22

Review 3.  Human(ized) monoclonal antibodies in atopic patients - state of the art.

Authors:  Arzu Didem Yalcin; Kevser Onbasi; Rusen Uzun; Felix Herth; Philipp Albert Schnabel
Journal:  Cent Eur J Immunol       Date:  2020-07-27       Impact factor: 2.085

4.  Pollen aero allergens and the climate in Mediterranean region and allergen sensitivity in allergic rhinoconjunctivitis and allergic asthma patients.

Authors:  Arzu Didem Yalcin; Saime Basaran; Atil Bisgin; Hasan Hüseyin Polat; Reginald M Gorczynski
Journal:  Med Sci Monit       Date:  2013-02-11

5.  IL-8, IL-10, TGF-β, and GCSF levels were increased in severe persistent allergic asthma patients with the anti-IgE treatment.

Authors:  Arzu D Yalcin; Atil Bisgin; Reginald M Gorczynski
Journal:  Mediators Inflamm       Date:  2012-12-19       Impact factor: 4.711
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.